SG10201808863UA - Combined chemical and genetic approaches for generation of induced pluripotent stem cells - Google Patents
Combined chemical and genetic approaches for generation of induced pluripotent stem cellsInfo
- Publication number
- SG10201808863UA SG10201808863UA SG10201808863UA SG10201808863UA SG10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA
- Authority
- SG
- Singapore
- Prior art keywords
- generation
- stem cells
- pluripotent stem
- induced pluripotent
- genetic approaches
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/605—Nanog
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/608—Lin28
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
- C12N2506/094—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells from keratinocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency. [Figure ] 82
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6995608P | 2008-03-17 | 2008-03-17 | |
US19798608P | 2008-10-31 | 2008-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201808863UA true SG10201808863UA (en) | 2018-11-29 |
Family
ID=41091504
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201607710UA SG10201607710UA (en) | 2008-03-17 | 2009-03-17 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
SG10201808863UA SG10201808863UA (en) | 2008-03-17 | 2009-03-17 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
SG2013019211A SG188904A1 (en) | 2008-03-17 | 2009-03-17 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
SG10202103401QA SG10202103401QA (en) | 2008-03-17 | 2009-03-17 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201607710UA SG10201607710UA (en) | 2008-03-17 | 2009-03-17 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013019211A SG188904A1 (en) | 2008-03-17 | 2009-03-17 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
SG10202103401QA SG10202103401QA (en) | 2008-03-17 | 2009-03-17 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
Country Status (16)
Country | Link |
---|---|
US (8) | US9534205B2 (en) |
EP (3) | EP2279243B1 (en) |
JP (6) | JP5951254B2 (en) |
KR (1) | KR101679082B1 (en) |
CN (2) | CN104694570B (en) |
AU (1) | AU2009225665B9 (en) |
BR (1) | BRPI0908708A2 (en) |
CA (1) | CA2718904C (en) |
ES (1) | ES2690554T3 (en) |
HK (2) | HK1151559A1 (en) |
IL (1) | IL208144B (en) |
MX (1) | MX2010010165A (en) |
RU (1) | RU2010139426A (en) |
SG (4) | SG10201607710UA (en) |
WO (1) | WO2009117439A2 (en) |
ZA (1) | ZA201006683B (en) |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110171185A1 (en) * | 1999-06-30 | 2011-07-14 | Klimanskaya Irina V | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof |
US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
EP2302034B1 (en) * | 2005-08-03 | 2020-10-14 | Astellas Institute for Regenerative Medicine | Improved methods of reprogramming animal somatic cells |
EP1942739B1 (en) | 2005-10-18 | 2010-12-08 | National Jewish Health | Conditionally immortalized long-term adult stem cells and methods of making and using such cells |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
EP2206724A1 (en) * | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
US20090227032A1 (en) * | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
CA2683056C (en) | 2007-04-07 | 2020-03-24 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
JP2008307007A (en) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth |
US9213999B2 (en) * | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
US20140342984A1 (en) * | 2007-10-19 | 2014-11-20 | Robert G. Matheny | Compositions for Regenerating Defective or Absent Myocardium |
ES2690554T3 (en) | 2008-03-17 | 2018-11-21 | The Scripps Research Institute | Combined chemical and genetic approaches for the generation of induced pluripotent stem cells |
EP2276834A4 (en) * | 2008-04-07 | 2012-02-08 | Nupotential Inc | Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator |
US20100279404A1 (en) | 2008-05-02 | 2010-11-04 | Shinya Yamanaka | Method of nuclear reprogramming |
SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
EP2300611B1 (en) | 2008-06-13 | 2017-08-09 | Whitehead Institute for Biomedical Research | Programming and reprogramming of cells |
EP2746387A1 (en) | 2008-07-21 | 2014-06-25 | Taiga Biotechnologies, Inc. | Differentiated anucleated cells and method for preparing the same |
US8298825B1 (en) * | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
DK2318435T3 (en) | 2008-08-28 | 2016-02-29 | Taiga Biotechnologies Inc | Modulators of MYC, methods of using the same, and methods for identifying agents that modulate MYC |
US9045737B2 (en) * | 2008-12-13 | 2015-06-02 | Dnamicroarray, Inc. | Artificial three-dimensional microenvironment niche culture |
EP2373784B1 (en) | 2008-12-17 | 2017-10-25 | The Scripps Research Institute | Generation and maintenance of stem cells |
EP2641911A3 (en) * | 2008-12-23 | 2014-01-01 | Vivoscript, Inc. | Compositions and methods for re-programming cells without genetic modification |
WO2010115052A2 (en) * | 2009-04-03 | 2010-10-07 | The Mclean Hospital Corporation | Induced pluripotent stem cells |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
JP5777113B2 (en) | 2009-05-29 | 2015-09-09 | 学校法人慶應義塾 | Method for selecting induced pluripotent stem cell clones |
JP5751548B2 (en) * | 2009-08-07 | 2015-07-22 | 国立大学法人京都大学 | Canine iPS cells and production method thereof |
AU2014250681B2 (en) * | 2009-10-16 | 2016-12-15 | The Scripps Research Institute | Induction of pluripotent cells |
BR112012008848A2 (en) * | 2009-10-16 | 2019-09-24 | Scripps Research Inst | in vitro or ex vivo method for inducing non-pluripotent mammalian cells into induced pluripotent stem cells |
AU2010312291A1 (en) | 2009-10-29 | 2012-06-21 | Mcmaster University | Generating induced pluripotent stem cells and progenitor cells from fibroblasts |
SG10201702120VA (en) * | 2009-10-31 | 2017-05-30 | Genesis Technologies Ltd | Methods for Reprogramming Cells and Uses Thereof |
WO2011056971A2 (en) * | 2009-11-04 | 2011-05-12 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
WO2011082038A2 (en) * | 2009-12-31 | 2011-07-07 | Fate Therapeutics, Inc. | Improved reprogramming compositions |
US20130059385A1 (en) * | 2010-03-02 | 2013-03-07 | The Scripps Research Institute | Methods of generating pluripotent stem cells |
EP2366432A1 (en) * | 2010-03-16 | 2011-09-21 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto |
JP5909482B2 (en) | 2010-03-31 | 2016-04-26 | ザ スクリプス リサーチ インスティテュート | Cell reprogramming |
CN102260646B (en) * | 2010-05-26 | 2015-09-16 | 北京瑞普晨创科技有限公司 | Prepare a method for induced pluripotent stem cells, test kit and purposes |
US9376664B2 (en) | 2010-06-14 | 2016-06-28 | The Scripps Research Institute | Reprogramming of cells to a new fate |
KR101861171B1 (en) | 2010-06-18 | 2018-05-31 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | Cardiomyocyte medium with dialyzed serum |
WO2012007725A2 (en) * | 2010-07-16 | 2012-01-19 | Plasticell Ltd | Method of reprogramming a cell |
WO2012030854A2 (en) | 2010-09-01 | 2012-03-08 | Whitehead Institute For Biomedical Research | Compositions and methods for modulating emt and uses thereof |
US20120064041A1 (en) * | 2010-09-03 | 2012-03-15 | Arshak Alexanian | Efficient Generation of Neurally-Induced Mesenchymal Stem Cells and Applications Thereof |
EP2616540A4 (en) * | 2010-09-14 | 2014-02-19 | Univ Kyoto | Method of efficiently establishing induced pluripotent stem cells |
EP2618829B1 (en) * | 2010-09-22 | 2019-05-01 | The Regents of the University of Colorado, a body corporate | Smad7 for use in the treatment of oral mucositis or psoriasis |
CN103384679B (en) * | 2010-12-17 | 2015-08-26 | 拜奥拉米那公司 | Restructuring Kallinin 21 |
WO2012087965A2 (en) | 2010-12-22 | 2012-06-28 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
EP2660314A4 (en) * | 2010-12-27 | 2014-09-03 | Lsip Llc | iPS CELLS AND METHOD FOR GENERATING SAME |
WO2012098260A1 (en) * | 2011-01-21 | 2012-07-26 | Axiogenesis Ag | A non-viral system for the generation of induced pluripotent stem (ips) cells |
ES2957478T3 (en) | 2011-05-02 | 2024-01-19 | Univ Wayne State | A protein-induced pluripotent stem cell technology and uses thereof |
WO2012166973A1 (en) * | 2011-06-01 | 2012-12-06 | Sanford-Burnham Medical Research Institute | Methods for promoting cell reprogramming |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
JP6113160B2 (en) * | 2011-07-19 | 2017-04-12 | ヴィヴォスクリプト,インコーポレイテッド | Compositions and methods for reprogramming cells without genetic modification to repair cartilage damage |
CN103703130A (en) | 2011-07-25 | 2014-04-02 | 国立大学法人京都大学 | Method for screening induced pluripotent stem cells |
CN103917641B (en) | 2011-10-21 | 2018-04-27 | 爱科来株式会社 | The cultivation of the single cell dispersion of the maintenance versatility carried out by laminar flow |
WO2013077423A1 (en) | 2011-11-25 | 2013-05-30 | 国立大学法人京都大学 | Method for culturing pluripotent stem cell |
US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
WO2013086008A1 (en) | 2011-12-05 | 2013-06-13 | Factor Bioscience Inc. | Methods and products for transfecting cells |
US20150017134A1 (en) * | 2012-03-01 | 2015-01-15 | Whitehead Institute For Biomedical Research | Emt-inducing transcription factors cooperate with sox9 |
EP2825637A4 (en) * | 2012-03-14 | 2015-12-23 | Childrens Medical Center | High-throughput image-based chemical screening in zebrafish blastomere cell culture |
EP3868387A1 (en) | 2012-07-20 | 2021-08-25 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10357517B1 (en) * | 2012-10-01 | 2019-07-23 | University Of South Florida | Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592 |
WO2014071219A1 (en) | 2012-11-01 | 2014-05-08 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
US10130637B2 (en) | 2012-11-02 | 2018-11-20 | Duke University | Inhibition of histone methyltransferase for cardiac reprogramming |
JP6509126B2 (en) | 2013-01-09 | 2019-05-08 | インターナショナル ステム セル コーポレイション | Small molecules that promote skin regeneration |
EP2955223B1 (en) | 2013-02-08 | 2019-12-18 | Kyoto University | Production methods for megakaryocytes and platelets |
JP6292415B2 (en) | 2013-03-06 | 2018-03-14 | 国立大学法人京都大学 | Pluripotent stem cell culture system and pluripotent stem cell passage method |
EP2964774B1 (en) | 2013-03-08 | 2020-05-06 | The Regents of The University of Colorado, A Body Corporate | Ptd-smad7 therapeutics |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) * | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
DK2970890T3 (en) | 2013-03-14 | 2020-05-04 | Brigham & Womens Hospital Inc | COMPOSITIONS AND PROCEDURES FOR THE PROMOTION AND CULTIVATION OF EPITHEL STEM CELLS |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
WO2014148646A1 (en) | 2013-03-21 | 2014-09-25 | 国立大学法人京都大学 | Pluripotent stem cell for neuronal differentiation induction |
JP6473686B2 (en) | 2013-03-25 | 2019-02-20 | 公益財団法人神戸医療産業都市推進機構 | Cell sorting method |
KR20140121317A (en) * | 2013-04-06 | 2014-10-15 | 서울대학교산학협력단 | Method for producing induced neural stem cell from non-neuronal cell, and induced neural stem cell produced by the same |
JP6461787B2 (en) | 2013-04-12 | 2019-01-30 | 国立大学法人京都大学 | Method for inducing alveolar epithelial progenitor cells |
JP6429280B2 (en) | 2013-05-14 | 2018-11-28 | 国立大学法人京都大学 | Efficient cardiomyocyte induction method |
US10159766B2 (en) | 2013-05-31 | 2018-12-25 | Iheart Japan Corporation | Layered cell sheet incorporating hydrogel |
WO2014200115A1 (en) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | Method for producing renal precursor cells, and drug containing renal precursor cells |
CN104278008B (en) * | 2013-07-12 | 2020-08-21 | 北京宏冠再生医学科技有限公司 | Method, kit and application for preparing pluripotent stem cells through small molecule compound treatment |
KR101655383B1 (en) | 2013-07-27 | 2016-09-08 | 고려대학교 산학협력단 | Composition for Maintaining Chromosome Stability of Pluripotent Stem Cells Comprising Small Molecules |
JP6378183B2 (en) | 2013-08-07 | 2018-08-22 | 国立大学法人京都大学 | Method for producing pancreatic hormone-producing cells |
KR102320537B1 (en) | 2013-09-05 | 2021-11-01 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | New method for inducing dopamine-producing neural precursor cells |
CN104419683A (en) * | 2013-09-10 | 2015-03-18 | 中国科学院生物物理研究所 | Method for preparing autologous induced pluripotent stem cells of patient with Fanconi anemia and application of method |
US10144915B2 (en) | 2013-10-23 | 2018-12-04 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Reprogramming fibroblasts into cardiomyocytes |
JP6415582B2 (en) | 2013-10-25 | 2018-10-31 | ウェイン ステート ユニバーシティー | Methods, systems, and compositions for cell transformation by protein-induced in vivo cell reprogramming |
KR102219743B1 (en) | 2013-11-01 | 2021-02-23 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Novel chondrocyte induction method |
US9512406B2 (en) | 2013-12-20 | 2016-12-06 | The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone | Generating hepatocytes |
MX2016009771A (en) | 2014-01-31 | 2016-11-14 | Factor Bioscience Inc | Methods and products for nucleic acid production and delivery. |
CN104894060B (en) * | 2014-03-03 | 2018-11-06 | 中国科学院上海生命科学研究院 | Inducing somatic transdifferentiation is the method and its application of neural stem cell |
EP3114214B1 (en) | 2014-03-04 | 2023-11-01 | Fate Therapeutics, Inc. | Improved reprogramming methods and cell culture platforms |
JP7012432B2 (en) | 2014-07-14 | 2022-01-28 | 中外製薬株式会社 | Methods for identifying protein epitopes |
US20170211091A1 (en) * | 2014-07-16 | 2017-07-27 | Fundación Pública Andaluza Progreso Y Salud | Methods for generating induced pluripotent stem cells |
WO2016022472A1 (en) * | 2014-08-04 | 2016-02-11 | University Of Kansas | Mammalian pluripotent stem cells, methods for their production, and uses thereof |
RU2565548C1 (en) * | 2014-08-05 | 2015-10-20 | Дмитрий Андреевич Журавлёв | Method of producing of pluripotent stem cells |
WO2016022930A1 (en) | 2014-08-07 | 2016-02-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Reversible stencils for fabricating micro-tissues |
US10568883B2 (en) * | 2014-09-03 | 2020-02-25 | Massachusetts Institute Of Technology | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
WO2016117139A1 (en) * | 2015-01-20 | 2016-07-28 | タカラバイオ株式会社 | Method for producing nervous system cells |
US20180112180A1 (en) | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
US10767165B2 (en) * | 2015-01-30 | 2020-09-08 | Centre National De La Recherche Scientifique (Cnrs) | Reprogramming method for producing induced pluripotent stem cells (iPSC) |
AU2016218977C1 (en) | 2015-02-13 | 2023-03-23 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
JP2018510649A (en) | 2015-02-17 | 2018-04-19 | ユニバーシティー ヘルス ネットワーク | Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular cardiomyocytes |
JP2016202172A (en) | 2015-04-16 | 2016-12-08 | 国立大学法人京都大学 | Production method of pseudoislet |
KR20180033537A (en) | 2015-07-21 | 2018-04-03 | 더 칠드런스 메디칼 센터 코포레이션 | PD-L1 expressing hematopoietic stem cells and uses |
CN108350433B (en) * | 2015-08-21 | 2021-11-30 | 京都府公立大学法人 | Osteoblast and method for producing the same |
CN117737124A (en) * | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | Platform for inducing and maintaining ground state pluripotency |
CN116024164A (en) * | 2015-10-21 | 2023-04-28 | 京都府公立大学法人 | Method for producing cells |
EP3400286A1 (en) | 2016-01-08 | 2018-11-14 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
EP3401392B1 (en) * | 2016-01-08 | 2022-02-23 | Evia Life Sciences Inc. | Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound |
US11096964B2 (en) * | 2016-01-20 | 2021-08-24 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US11413309B2 (en) | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
PT3444334T (en) | 2016-04-15 | 2021-09-08 | Univ Kyoto | Method for inducing cd8+ t cells |
JP7011260B2 (en) | 2016-04-22 | 2022-02-10 | 国立大学法人京都大学 | Method for producing dopamine-producing neural progenitor cells |
CN105943526B (en) * | 2016-05-18 | 2018-08-14 | 上海交通大学医学院附属上海儿童医学中心 | Applications of the PD0325901 in maintaining arterial duct to open |
EP3483262B1 (en) * | 2016-06-03 | 2021-11-17 | Institue of Transfusion Medicine, Academy of Military Medical Sciences, People's Liberation Army of China | Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application |
WO2018005799A1 (en) * | 2016-06-29 | 2018-01-04 | Georgia State University Research Foundation, Inc. | Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same |
CA3033788A1 (en) | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
EP3533865A4 (en) * | 2016-10-28 | 2020-04-15 | National Cancer Center | Method for preparing human hepatocyte progenitor cells |
CN113786476A (en) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | Nanoparticle formulations |
WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
KR102537361B1 (en) | 2016-12-27 | 2023-05-26 | 스미또모 가가꾸 가부시키가이샤 | Methods for evaluating and selecting artificial pluripotent stem cells, and methods for producing artificial pluripotent stem cells |
CN106754655B (en) * | 2016-12-29 | 2020-06-19 | 赛业(苏州)生物科技有限公司 | Animal embryo culture medium |
MX2019007890A (en) | 2016-12-30 | 2020-01-20 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells. |
CN110199017A (en) | 2017-01-20 | 2019-09-03 | 国立大学法人京都大学 | CD8 alpha+beta+cytotoxic T cell preparation method |
JP7162537B2 (en) | 2017-01-26 | 2022-10-28 | 国立大学法人大阪大学 | Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells |
WO2018168829A1 (en) | 2017-03-14 | 2018-09-20 | 国立大学法人京都大学 | Method for producing helper t cells from pluripotent stem cells |
KR20230150412A (en) | 2017-05-25 | 2023-10-30 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
KR102422175B1 (en) | 2017-06-19 | 2022-07-18 | 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 | Method for predicting differentiation capacity of pluripotent stem cells and reagents therefor |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US20190062711A1 (en) * | 2017-08-25 | 2019-02-28 | So Young Life Sciences Corporation | Use Of Phosphorylated TBeta4 And Other Factors To Generate Human Induced Pluripotent Stem Cells |
WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
EP3699267A4 (en) | 2017-10-17 | 2021-10-27 | Kyoto University | Method for obtaining artificial neuromuscular junction from pluripotent stem cells |
KR101810014B1 (en) | 2017-10-23 | 2018-01-18 | 차의과학대학교 산학협력단 | Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
KR101810008B1 (en) | 2017-10-23 | 2018-01-18 | 차의과학대학교 산학협력단 | Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents |
KR101998633B1 (en) * | 2017-10-31 | 2019-07-11 | 가톨릭관동대학교산학협력단 | Use of ellipticine for inducing differentiation of stem cells into chondrocytes |
CN108624562B (en) * | 2018-05-18 | 2021-11-02 | 首都医科大学附属北京朝阳医院 | Method for preparing tumor stem cells and special kit thereof |
KR102158783B1 (en) * | 2018-06-18 | 2020-09-22 | 한국생명공학연구원 | Cell reprogramming composition and method for producing an indueced pluripotent stem cell using the same |
BR112021000437A2 (en) | 2018-07-13 | 2021-04-06 | Kyoto University | METHODS FOR PRODUCING A DELTA RANGE T CELL AND FOR PREVENTING OR TREATING TUMOR, DELTA RANGE T CELL, CELL POPULATION, MEDICINE, EXTERMINATION AGENT FOR A CELL, AND, USE OF THE CELL |
JP7285015B2 (en) | 2018-07-19 | 2023-06-01 | 国立大学法人京都大学 | Lamellar cartilage derived from pluripotent stem cells and method for producing the same |
US20210332329A1 (en) | 2018-07-23 | 2021-10-28 | Kyoto University | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
CA3109647A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
WO2020116606A1 (en) | 2018-12-06 | 2020-06-11 | キリンホールディングス株式会社 | Production method for t cells or nk cells, medium for culturing t cells or nk cells, method for culturing t cells or nk cells, method for maintaining undifferentiated state of undifferentiated t cells, and growth-accelerating agent for t cells or nk cells |
US20220056413A1 (en) | 2018-12-21 | 2022-02-24 | Kyoto University | Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage |
US20220062341A1 (en) | 2018-12-26 | 2022-03-03 | Kirin Holdings Kabushiki Kaisha | Modified tcr and production method therefor |
CN113811316A (en) | 2019-05-15 | 2021-12-17 | 味之素株式会社 | Method for purifying neural crest cells or corneal epithelial cells |
EP3974519A4 (en) | 2019-05-20 | 2023-07-12 | Ajinomoto Co., Inc. | Expansion culture method for cartilage or bone precursor cells |
WO2021015228A1 (en) * | 2019-07-25 | 2021-01-28 | 富士フイルム株式会社 | Method for producing specific differentiated cells |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
CN112301052A (en) * | 2019-08-01 | 2021-02-02 | 浙江霍德生物工程有限公司 | Method for preparing induced multifunctional stem cells through somatic cell reprogramming |
CN115023233A (en) | 2019-12-12 | 2022-09-06 | 国立大学法人千叶大学 | Freeze-dried preparation comprising megakaryocytes and platelets |
KR102087084B1 (en) * | 2020-02-03 | 2020-03-10 | 주식회사 이에이치엘바이오 | Culture method of adipose-drived stem cell proliferation expressing anti-aging factors |
KR20220143063A (en) | 2020-02-19 | 2022-10-24 | 남미 테라퓨틱스, 인크. | Formulated and/or co-formulated liposome compositions containing TGFβ antagonist prodrugs useful for the treatment of cancer and methods thereof |
MX2022010521A (en) | 2020-02-28 | 2022-09-19 | Takeda Pharmaceuticals Co | Method for producing natural killer cells from pluripotent stem cells. |
US20230257705A1 (en) | 2020-06-17 | 2023-08-17 | Kyoto University | Chimeric antigen receptor-expressing immunocompetent cells |
WO2022014604A1 (en) | 2020-07-13 | 2022-01-20 | 国立大学法人京都大学 | Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells |
JPWO2022019152A1 (en) | 2020-07-20 | 2022-01-27 | ||
EP4202041A1 (en) | 2020-08-18 | 2023-06-28 | Kyoto University | Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells |
WO2022196714A1 (en) | 2021-03-17 | 2022-09-22 | アステラス製薬株式会社 | Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein |
TW202305112A (en) | 2021-04-30 | 2023-02-01 | 國立研究開發法人理化學研究所 | Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates |
WO2022255489A1 (en) | 2021-06-04 | 2022-12-08 | キリンホールディングス株式会社 | Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition |
CA3222761A1 (en) | 2021-06-10 | 2022-12-15 | Ajinomoto Co., Inc. | Method for producing mesenchymal stem cells |
AR126145A1 (en) | 2021-06-15 | 2023-09-13 | Takeda Pharmaceuticals Co | METHOD FOR PRODUCING NATURAL CYTOLYTIC LYMPHOCYTES FROM PLURIPOTENTIVE STEM CELLS |
WO2023283631A2 (en) * | 2021-07-08 | 2023-01-12 | The Broad Institute, Inc. | Methods for differentiating and screening stem cells |
WO2023286834A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level |
JPWO2023286832A1 (en) | 2021-07-15 | 2023-01-19 | ||
WO2023017848A1 (en) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells |
WO2023074648A1 (en) * | 2021-10-25 | 2023-05-04 | 富士フイルム株式会社 | Method for producing intestinal endocrine cells, pluripotent stem cell-derived intestinal endocrine cells, medium or medium kit, and use of the same |
CN116694551A (en) * | 2022-02-24 | 2023-09-05 | 清华大学 | Induced mature liver cell and preparation method thereof |
CN114702591B (en) * | 2022-05-17 | 2022-09-23 | 诺赛联合(北京)生物医学科技有限公司 | Preparation technology of adult cell-derived organoid |
JP7461691B1 (en) | 2023-06-23 | 2024-04-04 | 株式会社アンプリー | Carbon dioxide gas pack kit |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (en) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Ring gap magnet system |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
EP0710283A4 (en) * | 1993-07-22 | 1997-07-02 | Merck & Co Inc | EXPRESSION OF HUMAN INTERLEUKIN-1-g(b) IN A TRANSGENIC ANIMAL |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
GB9807935D0 (en) | 1998-04-14 | 1998-06-10 | Univ Edinburgh | Lineage specific cells and progenitor cells |
US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
ATE421329T1 (en) | 1997-05-07 | 2009-02-15 | Pharma Mar Sa | USE OF APLIDINE TO TREAT CARDIOVASCULAR DISEASES |
US6270994B1 (en) | 1997-06-13 | 2001-08-07 | Japanese Foundation For Cancer Research | Smad6 and uses thereof |
US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US20060263382A1 (en) | 1998-06-20 | 2006-11-23 | Richard Hotchkiss | Membrane-permeant peptide complexes for treatment of sepsis |
US6800790B2 (en) * | 1998-07-24 | 2004-10-05 | Carnegie Institution Of Washington | Method for maintenance and propagation of germline stem cells using members of the TFG-β family of growth factors |
GB9819912D0 (en) * | 1998-09-11 | 1998-11-04 | Univ Edinburgh | Propagation and/or derivation of embryonic stem cells |
WO2000040235A2 (en) | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Treatment of asthma with mek inhibitors |
US6703420B1 (en) | 1999-03-19 | 2004-03-09 | Bristol-Myers Squibb Pharma Company | Amino-thio-acrylonitriles as MEK inhibitors |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US20020142457A1 (en) * | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
US20030180947A1 (en) * | 2001-09-21 | 2003-09-25 | J.H. David Wu | Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression |
ES2388968T3 (en) | 2001-11-02 | 2012-10-22 | Giuliani International Limited | Smad7 inhibitors for the treatment of CNS diseases |
EP1480515B1 (en) * | 2002-03-05 | 2005-10-19 | ARTEMIS Pharmaceuticals GmbH | Inbred embryonic stem-cell derived mice |
GB0210539D0 (en) | 2002-05-08 | 2002-06-19 | Univ Edinburgh | Control of es cell self renewal and lineage specification, and medium therefor |
MXPA05003431A (en) | 2002-11-15 | 2005-07-05 | Warner Lambert Co | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer. |
CA2515215A1 (en) * | 2003-02-10 | 2004-08-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
AU2003901099A0 (en) | 2003-03-11 | 2003-03-27 | Es Cell International Pte Ltd. | Methods of inducing differentiation of stem cells |
US20070010008A1 (en) * | 2005-06-29 | 2007-01-11 | Tissuetech, Inc. | Ex vivo expansion of primary animal cells |
EP1732581A4 (en) | 2003-06-20 | 2008-06-04 | Univ California San Diego | Polypeptide transduction and fusogenic peptides |
CN103602633A (en) * | 2003-10-03 | 2014-02-26 | 福田惠一 | Method of inducing the differentiation of stem cells into myocardial cells |
GB2407048B (en) | 2003-10-15 | 2007-07-11 | Biotrace Internat Plc | Laboratory apparatus |
JP2007508026A (en) | 2003-10-16 | 2007-04-05 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ | Control of self-renewal and lineage specification of ES cells and culture medium therefor |
AU2004291559B2 (en) | 2003-11-19 | 2008-10-16 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
JP5102030B2 (en) | 2004-08-13 | 2012-12-19 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | Compositions and methods for self-renewal and differentiation in human embryonic stem cells |
US20080268533A1 (en) * | 2004-08-25 | 2008-10-30 | University Of Georgia Research Foundation, Inc. | Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells |
WO2006088867A2 (en) * | 2005-02-15 | 2006-08-24 | Medistem Laboratories, Incorporated | Method for expansion of stem cells |
CN101313065A (en) | 2005-08-01 | 2008-11-26 | 纽珀滕索有限公司 | Production of reprogrammed cells with restored potential |
WO2007030693A2 (en) | 2005-09-08 | 2007-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for promoting stem cell proliferation and survival |
BRPI0619704A2 (en) * | 2005-11-03 | 2011-10-11 | Vertex Pharma | compound, composition, method for inhibiting aurora kinase activity in a biological sample, method for treating a proliferative disorder and method for treating cancer |
US8217042B2 (en) * | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
JP2009515515A (en) * | 2005-11-11 | 2009-04-16 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ | Cell reprogramming and genetic modification |
US20090227032A1 (en) * | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
EP2206724A1 (en) * | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
WO2007069686A1 (en) | 2005-12-16 | 2007-06-21 | Meidensha Corporation | Vacuum capacitor and vacuum valve |
GB0601538D0 (en) * | 2006-01-26 | 2006-03-08 | Univ Birmingham | Epigenetic analysis |
JPWO2007088651A1 (en) | 2006-02-01 | 2009-06-25 | 国立大学法人 東京大学 | Combination use of TGF-β signal inhibitor and antitumor agent |
US7541186B2 (en) | 2006-02-22 | 2009-06-02 | University Of Washington | Method of generating human retinal progenitors from embryonic stem cells |
GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
TW200815597A (en) | 2006-03-30 | 2008-04-01 | Univ Edinburgh | Culture medium containing kinase inhibitors, and uses thereof |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
US20070259423A1 (en) | 2006-05-02 | 2007-11-08 | Jon Odorico | Method of differentiating stem cells into cells of the endoderm and pancreatic lineage |
GB2437737B (en) | 2006-05-04 | 2008-07-09 | Access Products Ltd | Scaffolding |
US7884107B2 (en) | 2006-06-30 | 2011-02-08 | Merck | Substituted piperidines that increase P53 activity and the uses thereof |
AU2007271964B2 (en) | 2006-07-14 | 2012-01-19 | Novartis Ag | Pyrimidine derivatives as ALK-5 inhibitors |
US20080020014A1 (en) | 2006-07-19 | 2008-01-24 | Paul Consigny | Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders |
GB0622395D0 (en) | 2006-11-09 | 2006-12-20 | Univ Cambridge Tech | Methods relating to pluripotent cells |
JP5419279B2 (en) | 2007-01-17 | 2014-02-19 | ウィスコンシン アラムニ リサーチ ファンデーション | Improved stem cell culture |
WO2008088882A2 (en) | 2007-01-19 | 2008-07-24 | The J. David Gladstone Institutes | Methods of generating cardiomyocytes |
CN103627671A (en) | 2007-01-30 | 2014-03-12 | 佐治亚大学研究基金会 | Method for generating endoderm and mesoderm lineages and multipotent migratory cells (MMC), and cell population and use |
WO2008105630A1 (en) | 2007-02-27 | 2008-09-04 | Procell Therapeutics Inc. | Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells |
EP3449923A1 (en) | 2007-03-07 | 2019-03-06 | MEI Pharma, Inc. | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
EP2147094B2 (en) * | 2007-04-18 | 2018-02-21 | Hadasit Medical Research Services & Development Limited | Stem cell-derived retinal pigment epithelial cells |
US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
JP2008307007A (en) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth |
CA2691793A1 (en) | 2007-06-29 | 2009-01-08 | Cellular Dynamics International, Inc. | Automated method and apparatus for embryonic stem cell culture |
WO2009032456A2 (en) | 2007-08-01 | 2009-03-12 | Primegen Biotech Llc | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
CN101855338B (en) * | 2007-08-31 | 2013-07-17 | 怀特黑德生物医学研究所 | WNT pathway stimulation in reprogramming somatic cells |
AU2008297024B2 (en) * | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
JP4604076B2 (en) * | 2007-11-07 | 2010-12-22 | 国立大学法人静岡大学 | Electrolyte membrane for fuel cell |
WO2009073523A2 (en) | 2007-11-29 | 2009-06-11 | Children's Hospital Of Orange County | De-differentiation of human cells |
AU2008329563A1 (en) | 2007-11-30 | 2009-06-04 | Cytomatrix Pty Ltd | Methods of inducing pluripotency involving Oct4 protein |
AU2008329562A1 (en) | 2007-11-30 | 2009-06-04 | Cytomatrix Pty Ltd | Methods of inducing pluripotency involving Sox2 protein |
WO2009082184A2 (en) | 2007-12-26 | 2009-07-02 | Posdata Co., Ltd. | Method for determining spurious and wireless communication system applying that method |
ES2690554T3 (en) * | 2008-03-17 | 2018-11-21 | The Scripps Research Institute | Combined chemical and genetic approaches for the generation of induced pluripotent stem cells |
US8298825B1 (en) * | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
EP2373784B1 (en) | 2008-12-17 | 2017-10-25 | The Scripps Research Institute | Generation and maintenance of stem cells |
WO2010102267A2 (en) * | 2009-03-06 | 2010-09-10 | Ipierian, Inc. | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
JP5777113B2 (en) * | 2009-05-29 | 2015-09-09 | 学校法人慶應義塾 | Method for selecting induced pluripotent stem cell clones |
AU2010279913B2 (en) * | 2009-08-07 | 2016-04-28 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
BR112012008848A2 (en) | 2009-10-16 | 2019-09-24 | Scripps Research Inst | in vitro or ex vivo method for inducing non-pluripotent mammalian cells into induced pluripotent stem cells |
ES2533581T3 (en) | 2010-03-05 | 2015-04-13 | Texas Heart Institute | ETS2 and Mesp1 generators of cardiac progenitors from fibroblasts |
JP5909482B2 (en) | 2010-03-31 | 2016-04-26 | ザ スクリプス リサーチ インスティテュート | Cell reprogramming |
JO3421B1 (en) | 2011-06-20 | 2019-10-20 | H Lundbeck As | Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
US9166832B1 (en) | 2013-10-04 | 2015-10-20 | Altera Corporation | Methods and apparatus for decision feedback equalization adaptation |
-
2009
- 2009-03-17 ES ES15177122.7T patent/ES2690554T3/en active Active
- 2009-03-17 BR BRPI0908708A patent/BRPI0908708A2/en not_active IP Right Cessation
- 2009-03-17 CN CN201510084514.4A patent/CN104694570B/en active Active
- 2009-03-17 EP EP09721278.1A patent/EP2279243B1/en active Active
- 2009-03-17 SG SG10201607710UA patent/SG10201607710UA/en unknown
- 2009-03-17 KR KR1020107023172A patent/KR101679082B1/en active IP Right Grant
- 2009-03-17 SG SG10201808863UA patent/SG10201808863UA/en unknown
- 2009-03-17 EP EP15177122.7A patent/EP2955222B1/en active Active
- 2009-03-17 EP EP18185585.9A patent/EP3409762A1/en active Pending
- 2009-03-17 SG SG2013019211A patent/SG188904A1/en unknown
- 2009-03-17 US US12/933,391 patent/US9534205B2/en active Active
- 2009-03-17 JP JP2011500906A patent/JP5951254B2/en active Active
- 2009-03-17 RU RU2010139426/10A patent/RU2010139426A/en not_active Application Discontinuation
- 2009-03-17 CN CN200980117686.XA patent/CN102027105B/en active Active
- 2009-03-17 MX MX2010010165A patent/MX2010010165A/en not_active Application Discontinuation
- 2009-03-17 SG SG10202103401QA patent/SG10202103401QA/en unknown
- 2009-03-17 WO PCT/US2009/037429 patent/WO2009117439A2/en active Application Filing
- 2009-03-17 CA CA2718904A patent/CA2718904C/en active Active
- 2009-03-17 AU AU2009225665A patent/AU2009225665B9/en active Active
-
2010
- 2010-03-12 US US12/723,063 patent/US9068170B2/en active Active
- 2010-04-02 US US12/753,386 patent/US9394524B2/en active Active
- 2010-09-14 IL IL208144A patent/IL208144B/en active IP Right Grant
- 2010-09-17 ZA ZA2010/06683A patent/ZA201006683B/en unknown
-
2011
- 2011-06-08 HK HK11105755.1A patent/HK1151559A1/en unknown
-
2013
- 2013-03-14 US US13/831,289 patent/US9540615B2/en active Active
-
2015
- 2015-01-28 JP JP2015013821A patent/JP2015119714A/en active Pending
- 2015-10-16 HK HK15110187.5A patent/HK1209457A1/en unknown
-
2016
- 2016-06-10 US US15/179,657 patent/US9771563B2/en active Active
- 2016-08-02 JP JP2016151681A patent/JP6321733B2/en active Active
- 2016-11-30 US US15/365,823 patent/US9926533B2/en active Active
-
2017
- 2017-08-23 US US15/684,851 patent/US20180002671A1/en not_active Abandoned
-
2018
- 2018-02-08 US US15/892,312 patent/US20180171303A1/en active Pending
- 2018-04-05 JP JP2018072807A patent/JP6899792B2/en active Active
-
2021
- 2021-06-15 JP JP2021099098A patent/JP7286710B2/en active Active
-
2023
- 2023-05-24 JP JP2023085020A patent/JP2023101613A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201808863UA (en) | Combined chemical and genetic approaches for generation of induced pluripotent stem cells | |
MX356756B (en) | Pluripotent stem cell culture on micro-carriers. | |
IN2014DN10996A (en) | ||
MX2010000348A (en) | Single pluripotent stem cell culture. | |
EP2896690A3 (en) | Use of RNA for reprogramming somatic cells | |
SG196784A1 (en) | Stem cell cultures | |
MX2013003681A (en) | Engineered nucleic acids and methods of use thereof. | |
WO2012021632A3 (en) | Generation and use of pluripotent stem cells | |
WO2008148105A8 (en) | Endometrial stem cells and methods of making and using same | |
WO2010129294A3 (en) | Small molecules supporting pluripotent cell growth and methods thereof | |
SG195299A1 (en) | Expansion of stem cells in hollow fiber bioreactors | |
EP2373784A4 (en) | Generation and maintenance of stem cells | |
EP2633036A4 (en) | Differentiation methods for production of glial cell populations | |
MY159971A (en) | Multipotent/pluripotent cells and methods | |
BR112014031424A2 (en) | pluripotent cell treatment | |
IL214529A0 (en) | Bioreactor for the cultivation of mammalian cells and methods of use thereof | |
MX344970B (en) | Cell culture medium for adamts protein expression. | |
EP2548950A3 (en) | Reprogramming T cells and hematopoietic cells | |
WO2011021194A3 (en) | Pericyte progenitor cells and methods of generating and using same | |
WO2011159684A3 (en) | Generation of induced pluripotent stem cells from small volumes of peripheral blood | |
WO2012064606A3 (en) | Tissue-specific extracellular matrix with or without tissue protein components for cell culture | |
IN2012DN00852A (en) | ||
WO2010022194A3 (en) | Compositions and methods for generation of pluripotent stem cells | |
WO2006130504A3 (en) | Methods for identifying ligands for stem cells and cells derived therefrom | |
EP2550356A4 (en) | Method of altering the differentiative state of a cell and compositions thereof |